Cell Technology's Im Vert
Executive Summary
Biological response modifier granted orphan status by FDA for use in treating primary brain cancer. Currently in Phase II study at 10 U.S. centers, the anticancer product could reach the market in late 1989 or early 1990, Boulder, Colo.-based Cell Technology says.